应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
KLRA Kailera Therapeutics, Inc.
盘前交易 04-22 07:17:42 EDT
25.22
+0.61
+2.48%
盘前
25.55
+0.33
+1.31%
07:00 EDT
最高
25.79
最低
23.70
成交量
84.31万
今开
24.87
昨收
24.61
日振幅
8.51%
总市值
29.75亿
流通市值
8.41亿
总股本
1.18亿
成交额
2,100万
换手率
2.53%
流通股本
3,333万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
减肥药企业Kailera纳斯达克上市:市值31亿美元 恒瑞医药成大赢家
雷递网 · 04-19
减肥药企业Kailera纳斯达克上市:市值31亿美元 恒瑞医药成大赢家
异动解读 | 凯莱拉治疗公司盘中大涨62.5%,受益于纳斯达克成功上市及减肥药市场广阔前景
异动解读 · 04-18
异动解读 | 凯莱拉治疗公司盘中大涨62.5%,受益于纳斯达克成功上市及减肥药市场广阔前景
美股异动 | 减肥药新贵Kailera Therapeutics(KLRA.US)登陆美股市场 开盘暴涨超50%
智通财经 · 04-18
美股异动 | 减肥药新贵Kailera Therapeutics(KLRA.US)登陆美股市场 开盘暴涨超50%
募资6.25亿美元创五年之最 减肥药新贵Kailera Therapeutics(KLRA.US)今晚登陆纳斯达克
智通财经 · 04-17
募资6.25亿美元创五年之最 减肥药新贵Kailera Therapeutics(KLRA.US)今晚登陆纳斯达克
减肥药公司Kailera Therapeutics(KLRA.US)IPO定价14-16美元/股 拟周五登陆纳斯达克
智通财经 · 04-14
减肥药公司Kailera Therapeutics(KLRA.US)IPO定价14-16美元/股 拟周五登陆纳斯达克
加载更多
公司概况
公司名称:
Kailera Therapeutics, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Kailera Therapeutics, Inc.于2024年5月8日根据特拉华州法律注册成立。该公司是一家处于临床阶段的生物技术公司,致力于通过推进多元化的研发管线,引领肥胖症治疗的新时代。目前,该公司正在快速推进四款处于临床阶段的候选产品,这些产品利用多种基于胰高血糖素样肽-1 (GLP-1) 的作用机制和给药途径。
发行价格:
--
{"stockData":{"symbol":"KLRA","market":"US","secType":"STK","nameCN":"Kailera Therapeutics, Inc.","latestPrice":25.22,"timestamp":1776801600000,"preClose":24.61,"halted":0,"volume":843103,"hourTrading":{"tag":"盘前","latestPrice":25.55,"preClose":25.22,"latestTime":"07:00 EDT","volume":212,"amount":5422.156944,"timestamp":1776855604143,"change":0.33,"changeRate":0.013085,"amplitude":0.032514},"delay":0,"changeRate":0.024786672084518464,"floatShares":33333334,"shares":117948773,"eps":0,"marketStatus":"盘前交易","change":0.61,"latestTime":"04-22 07:17:42 EDT","open":24.87,"high":25.79,"low":23.695,"amount":20997509.723605,"amplitude":0.085128,"askPrice":25.55,"askSize":4,"bidPrice":24.1,"bidSize":500,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776864600000},"marketStatusCode":1,"adr":0,"listingDate":1776398400000,"exchange":"NASDAQ","adjPreClose":25.22,"preHourTrading":{"tag":"盘前","latestPrice":25.55,"preClose":25.22,"latestTime":"07:00 EDT","volume":212,"amount":5422.156944,"timestamp":1776855604143,"change":0.33,"changeRate":0.013085,"amplitude":0.032514},"postHourTrading":{"tag":"盘后","latestPrice":25.7,"preClose":25.22,"latestTime":"19:48 EDT","volume":13850,"amount":354687.9469,"timestamp":1776815299632,"change":0.48,"changeRate":0.019033,"amplitude":0.019033},"volumeRatio":0.17833656061714717},"requestUrl":"/m/hq/s/KLRA","defaultTab":"news","newsList":[{"id":"2628766952","title":"减肥药企业Kailera纳斯达克上市:市值31亿美元 恒瑞医药成大赢家","url":"https://stock-news.laohu8.com/highlight/detail?id=2628766952","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628766952?lang=zh_cn&edition=full","pubTime":"2026-04-19 15:45","pubTimestamp":1776584754,"startTime":"0","endTime":"0","summary":"减肥药企业Kailera Therapeutics(股票代码:“KLRA”)日前在美国纳斯达克上市,发行价为16美元,发行3906万股,募资总额为6.24亿美元。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260419/6391221034231146037652788.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260419/6391221034231146037652788.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n33340/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["600276","LU1969619763.USD","IYW","QQQE","LU1146622755.USD","LU2097828714.EUR","NVIW.SI","QDTE","QQQA","BK0239","LU2289578879.USD","TQQQ","LU2097828805.USD","LU1023057109.AUD","LU1997244956.HKD","LU2097828474.EUR","TQQY","LU1820825898.SGD","LU2097828557.USD","QQQJ","QYLG","QID","QQQ","PSQ","JEPQ","LU1328615791.USD","BK0188","BK0196","LU2543165471.USD","LU1655091616.SGD","KLRA","LU0359201885.HKD","BK0028","LU1255011170.USD","LU0405327494.USD","LU1580142542.USD","QQQY","BK1191","GPIQ","LU1997245094.SGD","LU2488822045.USD","QLD","LU0359201612.USD","BK4007","NQmain","LU2097828631.EUR","ONEQ","LU1997245177.USD","LU2495084118.USD","FTEC","BK0183","LU2148510915.USD","BK1147","BK0060","01276","LU2580892789.USD","QQQM","SQQQ","LU1781817850.SGD","LU2328871848.SGD","LU0405327148.USD","BK0012","LU1064131003.USD","MNQmain","LU0359202008.SGD","LU1064130708.USD","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136289592","title":"异动解读 | 凯莱拉治疗公司盘中大涨62.5%,受益于纳斯达克成功上市及减肥药市场广阔前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1136289592","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136289592?lang=zh_cn&edition=full","pubTime":"2026-04-18 01:27","pubTimestamp":1776446849,"startTime":"0","endTime":"0","summary":"凯莱拉治疗公司今日盘中股价大幅上涨62.50%,引起了市场的广泛关注。此次股价大涨与公司成功登陆纳斯达克密切相关。消息显示,凯莱拉治疗公司首次公开募股以每股16美元的价格发行,而市场预期其开盘价将达到32美元,远高于发行价,这反映了投资者对公司的高度认可和强烈兴趣。凯莱拉治疗公司的主要候选产品ribupatide作为一种每周注射一次的GLP-1药物,目前正处于后期试验阶段,这进一步增强了市场对其未来商业化前景的信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628578522","title":"美股异动 | 减肥药新贵Kailera Therapeutics(KLRA.US)登陆美股市场 开盘暴涨超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628578522","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628578522?lang=zh_cn&edition=full","pubTime":"2026-04-18 00:00","pubTimestamp":1776441606,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,周五,减肥药新贵Kailera Therapeutics(KLRA.US)登陆美股市场,开盘暴涨超50%,报24.1美元,IPO价格为16美元。该公司创下2021年以来美国生物科技领域规模最大的IPO纪录。Kailera成立于2024年,是一家处于临床后期的生物科技公司,正在开发四种基于GLP-1的减肥药物,其中包括一款每周注射一次的药物和一款每日口服一次的药片,目前均已进入后期临床试验阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430273.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LENZ","BK4539","KLRA","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628221198","title":"募资6.25亿美元创五年之最 减肥药新贵Kailera Therapeutics(KLRA.US)今晚登陆纳斯达克","url":"https://stock-news.laohu8.com/highlight/detail?id=2628221198","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628221198?lang=zh_cn&edition=full","pubTime":"2026-04-17 11:33","pubTimestamp":1776396818,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,专注于肥胖症治疗的临床阶段生物科技公司Kailera Therapeutics Inc.通过扩大首次公开发行规模,成功募资6.25亿美元,创下2021年以来美国生物科技领域规模最大的IPO纪录。根据周四发布的一份声明,Kailera以每股16美元的价格出售了约3900万股股票。包括贝恩资本旗下Bain Capital Private Equity、Bain Capital Life Sciences和卡塔尔投资局在内的现有股东已表示,有意按IPO价格合计购买最多2.25亿美元的公司股票。此次IPO之前,Kailera已于去年10月通过B轮融资募资6亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["QQQA","IYW","BK4539","SQQQ","BK4139","NVIW.SI","ONEQ","BK4007","JEPQ","BK1147","FTEC","QLD","MNQmain","TQQY","KLRA","QDTE","QQQM","QQQE","QID","PSQ","QQQ","QQQJ","QYLG","TQQQ","QQQY","GPIQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627741817","title":"减肥药公司Kailera Therapeutics(KLRA.US)IPO定价14-16美元/股 拟周五登陆纳斯达克","url":"https://stock-news.laohu8.com/highlight/detail?id=2627741817","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627741817?lang=zh_cn&edition=full","pubTime":"2026-04-14 15:19","pubTimestamp":1776151188,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,专注于开发治疗肥胖症注射及口服GLP-1类药物的III期阶段生物技术公司Kailera Therapeutics于周一公布其首次公开募股条款。根据计划,Kailera 预计将于本周四晚间完成最终定价,并于次日在纳斯达克交易所挂牌交易。其核心候选药物ribupatide目前正在全球开展III期临床试验,这是一种每周一次注射的GLP-1/葡萄糖依赖性促胰岛素多肽受体双重激动剂肽。Kailera Therapeutics成立于2024年,计划在纳斯达克上市,股票代码为KLRA。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["QLD","BK4539","QQQE","MNQmain","JEPQ","FTEC","QDTE","KLRA","QQQA","TQQQ","BK1147","NVIW.SI","ONEQ","BK4007","QQQ","QID","GPIQ","BK4139","IYW","PSQ","QQQJ","SQQQ","QQQM","TQQY","QYLG","QQQY"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.kailera.com","stockEarnings":[{"period":"1week","weight":0.5762},{"period":"ytd","weight":0.5762}],"compareEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":0.0856},{"period":"3month","weight":0.0273},{"period":"6month","weight":0.0481},{"period":"1year","weight":0.3701},{"period":"ytd","weight":0.0325}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kailera Therapeutics, Inc.于2024年5月8日根据特拉华州法律注册成立。该公司是一家处于临床阶段的生物技术公司,致力于通过推进多元化的研发管线,引领肥胖症治疗的新时代。目前,该公司正在快速推进四款处于临床阶段的候选产品,这些产品利用多种基于胰高血糖素样肽-1 (GLP-1) 的作用机制和给药途径。","exchange":"NASDAQ","name":"Kailera Therapeutics, Inc.","nameEN":"Kailera Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kailera Therapeutics, Inc.(KLRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kailera Therapeutics, Inc.(KLRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kailera Therapeutics, Inc.,KLRA,Kailera Therapeutics, Inc.股票,Kailera Therapeutics, Inc.股票老虎,Kailera Therapeutics, Inc.股票老虎国际,Kailera Therapeutics, Inc.行情,Kailera Therapeutics, Inc.股票行情,Kailera Therapeutics, Inc.股价,Kailera Therapeutics, Inc.股市,Kailera Therapeutics, Inc.股票价格,Kailera Therapeutics, Inc.股票交易,Kailera Therapeutics, Inc.股票购买,Kailera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kailera Therapeutics, Inc.(KLRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kailera Therapeutics, Inc.(KLRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}